Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Mammographic densities in a one-year isoflavone intervention.

Maskarinec G, Williams AE, Carlin L.

Eur J Cancer Prev. 2003 Apr;12(2):165-9.

PMID:
12671541
2.

Various doses of soy isoflavones do not modify mammographic density in postmenopausal women.

Maskarinec G, Verheus M, Steinberg FM, Amato P, Cramer MK, Lewis RD, Murray MJ, Young RL, Wong WW.

J Nutr. 2009 May;139(5):981-6. doi: 10.3945/jn.108.102913. Epub 2009 Mar 25.

3.

Double-Blind Randomized 12-Month Soy Intervention Had No Effects on Breast MRI Fibroglandular Tissue Density or Mammographic Density.

Wu AH, Spicer D, Garcia A, Tseng CC, Hovanessian-Larsen L, Sheth P, Martin SE, Hawes D, Russell C, MacDonald H, Tripathy D, Su MY, Ursin G, Pike MC.

Cancer Prev Res (Phila). 2015 Oct;8(10):942-51. doi: 10.1158/1940-6207.CAPR-15-0125. Epub 2015 Aug 14.

4.

A 2-year soy intervention in premenopausal women does not change mammographic densities.

Maskarinec G, Takata Y, Franke AA, Williams AE, Murphy SP.

J Nutr. 2004 Nov;134(11):3089-94.

5.

Soy protein containing isoflavones and mammographic density in a randomized controlled trial in postmenopausal women.

Verheus M, van Gils CH, Kreijkamp-Kaspers S, Kok L, Peeters PH, Grobbee DE, van der Schouw YT.

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2632-8. doi: 10.1158/1055-9965.EPI-08-0344.

6.

Effects of soy isoflavones on mammographic density and breast parenchyma in postmenopausal women: a randomized, double-blind, placebo-controlled clinical trial.

Delmanto A, Nahas-Neto J, Traiman P, Uemura G, Pessoa EC, Nahas EA.

Menopause. 2013 Oct;20(10):1049-54. doi: 10.1097/GME.0b013e3182850270.

PMID:
23481125
7.

Epidemiologic studies of isoflavones & mammographic density.

Maskarinec G, Verheus M, Tice JA.

Nutrients. 2010 Jan;2(1):35-48. doi: 10.3390/nu2010035. Epub 2010 Jan 19. Review.

8.

Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165].

Atkinson C, Warren RM, Sala E, Dowsett M, Dunning AM, Healey CS, Runswick S, Day NE, Bingham SA.

Breast Cancer Res. 2004;6(3):R170-9. Epub 2004 Feb 24.

9.

Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer.

Powles TJ, Howell A, Evans DG, McCloskey EV, Ashley S, Greenhalgh R, Affen J, Flook LA, Tidy A.

Menopause Int. 2008 Mar;14(1):6-12. doi: 10.1258/mi.2007.007033.

PMID:
18380954
10.

Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial.

Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D, Heinz R, Zalles CM, Helenowski IB, Jovanovic BD, Franke AA, Bosland MC, Wang J, Hansen NM, Bethke KP, Dew A, Coomes M, Bergan RC.

Cancer Prev Res (Phila). 2012 Feb;5(2):309-19. doi: 10.1158/1940-6207.CAPR-11-0251.

11.

Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial.

Levis S, Strickman-Stein N, Ganjei-Azar P, Xu P, Doerge DR, Krischer J.

Arch Intern Med. 2011 Aug 8;171(15):1363-9. doi: 10.1001/archinternmed.2011.330.

PMID:
21824950
12.

Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study.

Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R.

Maturitas. 2007 Nov 20;58(3):249-58. Epub 2007 Oct 29.

PMID:
17913408
13.

Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women.

Frankenfeld CL, McTiernan A, Aiello EJ, Thomas WK, LaCroix K, Schramm J, Schwartz SM, Holt VL, Lampe JW.

Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1156-62.

14.

Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study.

Burke GL, Legault C, Anthony M, Bland DR, Morgan TM, Naughton MJ, Leggett K, Washburn SA, Vitolins MZ.

Menopause. 2003 Mar-Apr;10(2):147-53.

PMID:
12627040
15.

Dietary phytoestrogen intake and mammographic density -- results of a pilot study.

Nagel G, Mack U, von Fournier D, Linseisen J.

Eur J Med Res. 2005 Sep 12;10(9):389-94.

PMID:
16183551
16.

Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.

Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC.

J Natl Cancer Inst. 1994 Mar 16;86(6):431-6.

PMID:
8120917
17.

Isoflavones and cognitive function in older women: the SOy and Postmenopausal Health In Aging (SOPHIA) Study.

Kritz-Silverstein D, Von Mühlen D, Barrett-Connor E, Bressel MA.

Menopause. 2003 May-Jun;10(3):196-202.

PMID:
12792289
18.

Soy isoflavones: no effects on bone mineral content and bone mineral density in healthy, menstruating young adult women after one year.

Anderson JJ, Chen X, Boass A, Symons M, Kohlmeier M, Renner JB, Garner SC.

J Am Coll Nutr. 2002 Oct;21(5):388-93.

PMID:
12356779
19.

Randomized controlled trial of whole soy and isoflavone daidzein on menopausal symptoms in equol-producing Chinese postmenopausal women.

Liu ZM, Ho SC, Woo J, Chen YM, Wong C.

Menopause. 2014 Jun;21(6):653-60. doi: 10.1097/GME.0000000000000102.

PMID:
24149925
20.

A randomized isoflavone intervention among premenopausal women.

Maskarinec G, Williams AE, Inouye JS, Stanczyk FZ, Franke AA.

Cancer Epidemiol Biomarkers Prev. 2002 Feb;11(2):195-201.

Supplemental Content

Support Center